9464D Syngeneic Model Service for Neuroblastoma

The 9464D syngeneic model service for neuroblastoma is an immune-competent C57BL/6 platform built on the transplantable TH-MYCN tumor line — a MYCN-driven, GD2-expressing, MHC-I-low neuroblastoma that reproduces the immunologically cold phenotype and NK-cell-dependent surveillance of human high-risk disease. Alfa Cytology delivers this model as a complete preclinical capability — covering authenticated 9464D / 9464D-GD2 / reporter-engineered expansion and banking, subcutaneous, intra-adrenal, or experimental-metastatic implantation, scheduled caliper and in vivo bioluminescence monitoring, and full neuroblastoma histopathology with GD2 and checkpoint immunophenotyping — all configured around each sponsor’s anti-GD2 construct, checkpoint combination, radio-immunotherapy, or microenvironment hypothesis.

Overview of 9464D Syngeneic Model for Neuroblastoma

9464D descends from the most genetically faithful mouse model of human neuroblastoma: the TH-MYCN transgenic mouse developed by William Weiss’s laboratory at UCSF, in which tyrosine-hydroxylase-driven MYCN overexpression drives tumors that closely mirror the histology, gene expression, and molecular signature of human high-risk disease. From a spontaneous tumor of this model, Hansford and colleagues established the transplantable line 9464D in 2004, and its defining biology maps almost point-for-point onto the human disease: it is MYCN-driven, carries a low tumor mutation burden, endogenously expresses the neuroblastoma antigen GD2 (though at lower surface levels than many human lines), and displays low MHC class I expression with only about a quarter of cells capable of upregulating it under interferon-γ — the molecular signature of the “cold” high-risk tumors that resist T-cell attack in patients. The immunological characterization published in 2014 completed the picture: the adaptive immune system exerts little influence on 9464D growth out of the box, yet depletion of NK1.1⁺ cells accelerates tumor outgrowth even in Rag1-deficient animals, formally demonstrating that NK cells — not T cells — are the principal natural effectors against this tumor; and the tumor-infiltrating leukocyte landscape, rich in myeloid suppressor cells and regulatory T cells, reproduces the immunosuppressive microenvironment of human neuroblastoma.

Fig 1. Average and individual tumor growth curves of 9464D syngeneic tumors in C57BL/6 mice alongside survival and H&E histology, benchmarking 9464D against NXS2 and TH-MYCN primary tumors in the preclinical neuroblastoma model panel. (Webb, Emily R., et al., 2020)

What has made 9464D the default neuroblastoma immunotherapy model is how productively its coldness has been engineered around. To study anti-GD2 antibody therapy — the standard of care built around dinutuximab — investigators overexpressed GD3 synthase and GM2/GD2 synthase in the parental line to generate 9464D-GD2, whose dinutuximab suppression of established flank tumors in vivo was complete until resistance was deliberately induced by tumor-derived small extracellular vesicles — an experiment that identified farnesyltransferase inhibitor tipifarnib as an adjunct to rescue anti-GD2 efficacy. A complementary IFN-γ-inducible MHC-I subclone, 9464D-GD2-I, enabled the mechanistic demonstration that local radiation converts cold tumors into T-cell-inflamed ones whose checkpoint blockade then succeeds — the radio-immunotherapy paradigm now central to neuroblastoma immunotherapy development. Orthotopic intra-adrenal implantation has been shown to grow faster than flank grafts with a denser, more M2-like macrophage infiltrate, and combinations of cyclophosphamide with anti-GD2 or anti-4-1BB have extended survival in that setting. The parent line’s honest limitation is metastasis: 9464D itself forms spontaneous metastases poorly — two liver metastases emerged from thirty intravenously infused mice — and those rare metastases have been captured as the M1 and M2 derivative lines, which metastasize with 100% penetrance to liver and bone respectively and model the organotropism of human high-risk disease. Reporter engineering with luciferase and tdTomato completes a platform in which an immunologically faithful primary tumor, engineered antigen variants, and true metastatic derivatives coexist in a single C57BL/6 system.

Cell line Information: 9464D

The table below consolidates the key biological, genetic, and modeling characteristics of the 9464D line and its engineered derivatives.

Our Services

An immunologically cold tumor is won or lost on engineering and analytics, and Alfa Cytology runs 9464D accordingly: authenticated banks of the parental, GD2-engineered, inducible-MHC-I, and reporter lines, validated flank, intra-adrenal, and intravenous formats with the platform’s metastasis caveats respected, scheduled caliper and in vivo bioluminescence monitoring, and endpoint pathology pairing GD2 expression with NK- and T-cell immunophenotyping — all under one accountable preclinical operation.

Workflow of 9464D Syngeneic Model Construction

Construction follows the published methodologies for each deployment format: 9464D or its engineered derivatives are expanded under authenticated conditions, implanted subcutaneously, intra-adrenally, or intravenously into C57BL/6 mice, grown to a standardized baseline, randomized, treated, and analyzed with neuroblastoma-appropriate efficacy and immune endpoints. The workflow comprises the following stages.

1. Cell authentication and banking: 9464D or derivative lines are provenance-verified, confirmed mycoplasma-negative by PCR, checked for MYCN expression and GD2/MHC-I status by flow cytometry, and expanded into low-passage working banks under the validated DMEM formulation with selection maintained where engineered.
2. Cell harvest and formulation: Healthy cultures are trypsinized, washed, counted and viability-checked, then resuspended at the study-specified dose of 0.5 × 10⁶ to 1 × 10⁶ cells (flank) or 0.25–2 × 10⁶ cells (metastatic arms) in 100 μL of PBS.
3. Anesthesia and implantation: C57BL/6 mice are anesthetized with isoflurane; cells are implanted subcutaneously into the flank, injected into the adrenal gland through a small abdominal approach for orthotopic arms, or infused intravenously via tail vein for experimental-metastasis designs.
4. Establishment monitoring and randomization: Flank and orthotopic tumors are measured by caliper from first palpability; metastatic arms are tracked by in vivo bioluminescence after D-luciferin administration; animals are randomized once tumors reach protocol-specified baselines.
5. Treatment administration: Experimental arms — anti-GD2 monoclonals and next-generation constructs, checkpoint inhibitors, local radiation fractions, farnesyltransferase and myeloid-targeting adjuncts, and combinations — proceed per study design with body-weight and toxicity monitoring.
6. Immune monitoring: Tumor-infiltrating leukocytes are profiled ex vivo for NK-cell, CD8⁺ T-cell, myeloid-suppressor, and Treg composition by multi-parametric flow cytometry; GD2 and MHC-I surface expression are re-quantified at endpoint; NK-dependence depletion arms are included where the design requires.
7. Endpoint and histopathological analysis: Endpoints integrate tumor-growth inhibition, metastatic burden by imaging and ex vivo organ mapping, and survival with histopathology (H&E confirming neuroblastoma morphology, plus GD2, synaptophysin, Ki67, CD8, NK1.1, and PD-L1 immunohistochemistry) and terminal mechanistic sampling for resistance studies.

Fig 2. 9464D Syngeneic Model construction workflow.

Case Study-9464D Syngeneic Model Development

Alfa Cytology has conducted preclinical programs on the 9464D platform spanning anti-GD2 construct evaluation, radio-immunotherapy combination assessment, and metastatic-disease studies with M1/M2 derivative lines. In these studies, implanted 9464D tumors were monitored through scheduled caliper and in vivo imaging measurements, treated per randomized regimens, and characterized at endpoint by histopathology with GD2 and immune-microenvironment immunophenotyping. Study-level datasets are available upon request.

Why Choose Alfa Cytology?

Alfa Cytology pairs neuroblastoma-model operational experience with cold-tumor engineering discipline, so every 9464D study is executed with verified lineage, validated format-specific workflows, and immunophenotyping that reflects the platform’s NK-surveilled biology.

• Focused experience with the TH-MYCN lineage, including parental, GD2-engineered, inducible-MHC-I, and reporter variants under documented provenance authentication.
• A single coordinated team managing cell banking, flank/orthotopic/intravenous implantation, in vivo imaging, and endpoint pathology under one quality framework.
• Design fluency with anti-GD2, checkpoint, radio-immunotherapy, and sEV-rescue formats, including NK-dependence depletion arms.
• Endpoint panels pairing neuroblastoma histology with GD2, synaptophysin, and NK/T-cell immunohistochemistry plus flow-cytometric TIL profiling.
• Transparent milestone reporting and rapid scientific feedback throughout the engagement.

Contact Us

If your neuroblastoma program needs an immunologically faithful, MYCN-driven syngeneic platform — with GD2-engineered variants and true metastatic derivatives — Alfa Cytology is ready to build the study around your construct. Reach out to us with your regimen and endpoint requirements, or contact us today for a customized proposal and quotation for the 9464D syngeneic model service.

For research use only. Not intended for any clinical use.